Key result
Thoracic lobaplatin plus endostar boosts objective response odds ~308% vs lobaplatin alone for malignant pleural effusions.
Why the study?
The efficacy and safety of thoracic perfusion of lobaplatin combined with endostar for treating malignant pleural effusions were not well established.
Does thoracic perfusion of lobaplatin combined with endostar improve objective response rate and disease control rate in patients with malignant pleural effusions compared to lobaplatin alone or cisplatin combined with endostar?
Meta-Analysis (n=651)
Does thoracic perfusion of lobaplatin combined with endostar improve objective response rate and disease control rate in patients with malignant pleural effusions compared to lobaplatin alone or cisplatin combined with endostar?
Thoracic perfusion of lobaplatin combined with endostar improves tumor response and quality of life in patients with malignant pleural effusions compared to lobaplatin alone, with a better safety profile than cisplatin combined with endostar.
Answers are grounded in this paper and cite their sources.
Supports lobaplatin-endostar perfusion for malignant pleural effusions; extends meta-analytic evidence beyond lobaplatin monotherapy.
INTRODUCTION: Lobaplatin is a new platinum-based cytotoxic chemotherapeutic agent. Endostar is an endogenous angiogenic inhibitor with implicated anti-tumor activity. This study was to investigate the efficacy and safety of thoracic perfusion of lobaplatin combined with endostar in the treatment of malignant pleural effusions (MPE). METHODS: We searched the databases of Pubmed, the Cochrane Library, Embase, WanFang Data, and CNKI to select the studies regarding the efficacy and safety of lobaplatin combined with endostar to treat MPE. A total of 10[3-12] randomized controlled trials with 651 patients were included. RESULTS: The objective response rate (P < .001, odds ratio = 4.08) and disease control rate (P < .001, odds ratio = 3.69) of lobaplatin combined with endostar were significantly higher than lobaplatin alone. In addition, lobaplatin combined with endostar remarkably promoted the quality of life of patients (P < .001, odds ratio = 3.93) compared with lobaplatin alone. Lobaplatin combined with endostar also promoted the quality of life of patients (P < .05, odds ratio = 2.56) compared with cisplatin combined with endostar. At the same time, the leukopenia rate (P < .05, odds ratio = .40) and the incidence of nausea and vomiting (P < .05, odds ratio = .38) of lobaplatin combined with endostar were significantly lower than that of cisplatin combined with endostar. CONCLUSIONS: The efficacy of lobaplatin combined with endostar was superior to lobaplatin alone. The safety was higher than cisplatin combined with endostar through thoracic perfusion in treating MPE, which indicated that lobaplatin combined with endostar could be the effective agent for controlling MPE.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) conducted a meta-analysis in Malignant pleural effusions (n=651). Thoracic perfusion of lobaplatin combined with endostar vs. Lobaplatin alone was evaluated on Objective response rate (OR 4.08, p=< .001). Thoracic perfusion of lobaplatin combined with endostar significantly improved the objective response rate compared to lobaplatin alone (OR 4.08; P<.001) for malignant pleural effusions.
Synapse has enriched 10 related papers. Consider them for comparative context: